NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXTC:
- NextCure Provides Business Update and Reports Full Year 2023 Financial Results
- NextCure’s treatment of AML granted FDA orphan designation
- NextCure publishes preclinical data on function of FLRT3
- NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
